Hua Xin, Long Zhi-Qing, Wang Si-Fen, Xu Fei, Wang Meng-Di, Chen Jia-Yi, Zhang Yu-Ling, Ni Wei-Qiong, Gao Yun-Sheng
Department of Radiation Oncology, Shanghai Jiao Tong University Medical School Affiliated Ruijin Hospital, Shanghai, China.
State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, China.
Front Nutr. 2023 Jul 20;10:1162280. doi: 10.3389/fnut.2023.1162280. eCollection 2023.
Recent studies indicate that the novel lymphocyte-C-reactive protein ratio (LCR) is strongly associated with the survival of various tumors, but its prognostic value in nasopharyngeal carcinoma (NPC) is understudied. This study aimed to explore the relationship between LCR and overall survival (OS) in NPC and develop a predictive model.
A total of 841 NPC patients who received concurrent chemoradiotherapy (CCRT) between January 2010 and December 2014 were retrospectively enrolled and randomly divided into a training cohort ( = 589) and a validation cohort ( = 252), and 122 patients between January 2015 and March 2015 were included as an additional validation cohort. Univariate and multivariate Cox analyses were performed to identify variables associated with OS and construct a predictive nomogram. The predictive accuracy of the nomogram was evaluated and independently validated.
The LCR score differentiated NPC patients into two groups with distinct prognoses (HR = 0.53; 95% CI: 0.32-0.89, = 0.014). Multivariate analysis showed that age, T stage, N stage, EBV-DNA status, and LCR score were independently associated with OS, and a predictive nomogram was developed. The nomogram had a good performance for the prediction of OS [C-index = 0.770 (95% CI: 0.675-0.864)]. and outperformed the traditional staging system [C-index = 0.589 (95% CI: 0.385-0.792)]. The results were internally and additionally validated using independent cohorts.
The pretreatment LCR could independently predict the overall survival in NPC patients. A novel LCR-based prognostic model of an easy-to-use nomogram was established, and it outperformed the conventional staging system in terms of predictive power. Further external verification remains necessary.
近期研究表明,新型淋巴细胞与C反应蛋白比值(LCR)与多种肿瘤的生存率密切相关,但其在鼻咽癌(NPC)中的预后价值研究较少。本研究旨在探讨LCR与NPC患者总生存期(OS)之间的关系,并建立一个预测模型。
回顾性纳入2010年1月至2014年12月期间接受同步放化疗(CCRT)的841例NPC患者,并随机分为训练队列(n = 589)和验证队列(n = 252),另外将2015年1月至2015年3月期间的122例患者纳入作为额外验证队列。进行单因素和多因素Cox分析以确定与OS相关的变量,并构建预测列线图。评估列线图的预测准确性并进行独立验证。
LCR评分将NPC患者分为两组,预后明显不同(HR = 0.53;95% CI:0.32 - 0.89,P = 0.014)。多因素分析表明,年龄、T分期、N分期、EBV - DNA状态和LCR评分与OS独立相关,并建立了预测列线图。该列线图在预测OS方面表现良好 [C指数 = 0.770(95% CI:0.675 - 0.864)],并且优于传统分期系统 [C指数 = 0.589(95% CI:0.385 - 0.792)]。结果在内部和额外使用独立队列进行了验证。
治疗前LCR可独立预测NPC患者的总生存期。建立了一种基于LCR的新型预后模型,该模型易于使用,在预测能力方面优于传统分期系统。仍需进一步的外部验证。